Europe ready to embrace first copies of biotech cancer drugs
LONDON (Reuters) - Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche's blood cancer drug Rituxan likely to hit the market imminently followed by a rival to its breast cancer medicine Herceptin.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Health | Herceptin | Rituxan